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Background: Erdheim-Chester disease is a rare histiocytosis characterized by multi-systemic organ involvement.
Immune-modulating agents such as interferon-alpha have limited success and the disorder is progressive and
causes high morbidity and mortality. Treatment with the BRAF-inhibitor vemurafenib has recently produced
substantial improvement in three patients with Erdheim-Chester disease expressing the p. V600E BRAF mutation.
The disorder commonly affects the central nervous system and it is not yet known whether vemurafenib can
reverse intra-axial infiltration and the resulting neurological impairment.
Case presentation: In this work, we report for the first time an excellent clinical response to vemurafenib in a
Norwegian patient with debilitating progressive spastic paraparesis due to intra-axial infiltration of the thoracic
spinal cord. The patient had been unresponsive to interferon-alpha. Low dose vemurafenib (720 mg daily) for a
period of three months resulted in significant tumor shrinkage by >60% and regression of contrast enhancement
and fluorodeoxyglucose uptake on positron-emission tomography. The patient’s spastic paraparesis and gait
function improved dramatically. She currently walks unaided and reports a substantially improved quality of life.
Conclusion: Our findings show that vemurafenib therapy, even at low doses, can be effective for the treatment of
intra-axial central nervous system involvement in BRAF-positive Erdheim-Chester disease.
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Erdheim-Chester disease (ECD) is a rare form of non-
Langerhans histiocytosis characterized by widespread,
multi-systemic infiltration by histiocytes that express
CD68, but not CD1a or S-100 protein [1]. Commonly
affected organs include the skeleton, skin, thoracic and
abdominal internal organs and the central nervous system
(CNS). In the nervous system, ECD commonly affects
the neurohypophysis causing diabetes insipidus. Ap-
proximately a third of the cases with CNS disease show
extrahypophyseal involvement comprising intra-axial
infiltrative lesions, meningioma-like masses and peri-
arterial infiltration [1-3]. Spinal cord involvement may
also occur due to either extramedullary masses or
intra-axial infiltration [1,4-6].* Correspondence: charalampos.tzoulis@helse-bergen.no
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unless otherwise stated.Interferon-alpha, which is commonly used as first-line
therapy, has limited effectivity and chronic use may be
complicated by severe side effects [7]. Various second-line
agents have been used including anakinra [8], cladribine
[9], infliximab [10] and tyrosine kinase inhibitors [11], but
systematic data are lacking and the effectivity of these
therapies remains unknown. ECD has an invariably pro-
gressive course and is associated with high morbidity.
Mortality rate was found to be 22% in one large study
[1,12-14].
It was recently shown that approximately 54% of the
patients with ECD and 57% of patients with Langerhans
cell histiocytosis harbor a somatic gain-of-function mu-
tation (p. V600E) in the protooncogene BRAF. This mu-
tation leads to activation of the tumorigenic RAS-ERK
pathway and is thought to play a key role in the patho-
genesis of the disorder [15]. A trial of vemurafenib, a
specific inhibitor of mutant BRAF resulted in substantial
clinical improvement in three patients with ECD andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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effective therapeutic option for these severe disorders.
We report an excellent clinical response to vemurafe-
nib in an ECD patient with spastic paraparesis secondary
to an intramedullary infiltrative lesion. This is the first
report of vemurafenib response in ECD with intra-axial
CNS infiltration. Our findings show that vemurafenib
therapy is effective for the treatment of infiltrative CNS
lesions in BRAF-positive ECD.
Case presentation
A now 34 year old female of Norwegian origin was
referred to us at the age of 31 with a 10 year history of
progressive spastic paraparesis due to an intramedullary
tumor. Her history and clinical features at the time of
diagnosis have been described elsewhere in detail [17].
MRI of the head and spine showed diffuse cerebellar
leukoencephalopathy, multiple vertebral changes with a
hypointense appearance on T1 and T2 sequences and an
intramedullary tumor in the spinal cord extending from
the 4th-6th thoracic vertebrae. Scintigraphy with techne-
tium 99 (Tc99) and fluorodeoxyglucose positron-emission
tomography (FDG-PET) showed extensive tracer uptake
in the epiphyseal long bones, spine and skull and hyper-
metabolism in the cord tumor. She also had hypophyseal
involvement with central diabetes insipidus and hypo-
gonadotropic hypogonadism. Bone marrow biopsy of a
vertebral lesion was performed to confirm the diagnosis of
ECD.
The patient was given interferon-alpha for a period of
three years during which her intramedullary tumor grad-
ually expanded accompanied by progressive worsening
of her spastic paraplegia. At the time of this study (base-
line evaluation) she could walk short distances with the
help of two crutches, was severely unsteady and had
experienced several falls (Table 1).
In order to determine the patient’s BRAF status, her
vertebral biopsy was stained with appropriate markers
and severely affected areas identified, dissected and
tested for mutations. The biopsy was stained withTable 1 Clinical and functional measures before and
during therapy with vemurafenib
Measure Baseline 1 month 3 months
Tumor size (mm2) 142 65 58.8
Spasticity knee (Ashworth scale) 2 2 1
Spasticity ankle (Ashworth scale) 1 1 0
Walking aids two crutches variable none
Gait test* 300 370 m 405 m
Legg press 30 kg not done 70 kg
Treadmill 1 km 1-2 km 3 km
Tumor size is given in area of the largest cross section through the tumor.
*Maximal distance at fast walking pace during 6 minutes.hematoxylin-eosin and immunohistochemically with
monoclonal mouse anti-human CD68, clone PGM1,
diluted 1:100, polyclonal rabbit anti-human CD3, di-
luted 1:400, and monoclonal mouse anti-human CD1a,
diluted 1:500 (all from DAKO Glostrup, Denmark)
(Figure 1).
The most severely affected area of the biopsy was
identified and macroscopically dissected. The dissected
material was treated in deparaffinization solution (Qiagen,
Hilden, Germany), extracted in ATL lysis buffer (Qiagen,
Hilden, Germany) and digested overnight with proteinase
K (Qiagen, Hilden, Germany) at 56°C, as previously de-
scribed [18]. DNA was extracted using the DSP DNA
mini kit (Qiagen, Hilden, Germany) on an automated
(QIAsymphony) platform (Qiagen, Hilden Germany).
BRAF mutations were analysed by real time PCR
(Rotor-Gene Q) using an allele-specific mutation detection
kit from Qiagen (Therasceen BRAF RGQ, Manchester, UK)
according to the manufacturer’s protocol. The biopsy
material tested positive for the common BRAF p. V600E
mutation.
The patient was started with vemurafenib 960 mg daily
(480 mg bid). Treatment response was monitored at
baseline (one week before treatment), and at one and
three months after treatment start. At each point the pa-
tient was evaluated by MRI of the CNS, whole-body
FDG-PET and clinical assessment including Ashworth
spasticity grading. Gait function and lower limb strength
were assessed by treadmill, weight lifting by leg-press
and a standardized gait-test testing maximal distance at
fast walking pace during a six minute period.
In addition, she underwent thorough cardiological and
dermatological examination. Routine blood count and
chemistry and electrocardiography were performed
monthly.
After the first week of treatment with vemurafenib the
patient developed side-effects in the form of severe skel-
etal pain and joint rubor and swelling. Side-effects were
dose-dependent and subsided completely when the dose
was reduced to 720 mg daily (240 mg + 480 mg), which
she currently uses. Vemurafenib treatment resulted in
significant clinical and functional improvement, which
was already evident by the end of the first month and is
ongoing. The clinical and functional measures of the
patient’s condition are summarized in Table 1.
The intramedullary lesion regressed in size by >60% to
nearly normal cord thickness, consistent with partial
remission according to Response Evaluation Criteria In
Solid Tumors (RECIST) criteria. Also, the lesion showed
normalization of T2 signal and loss of contrast enhance-
ment suggesting restoration of the local blood–brain
barrier. FDG-PET showed substantial reduction of tracer
uptake in the cord lesion and skeletal changes (Figure 2).
The patient’s spastic paraparesis and gait function improved
Figure 1 Pathology. Serial sections of the patient’s vertebral trephine biopsy showing normal (black arrows) and affected (white arrows) bone
marrow. Sections have been stained with hematoxylin-eosin (A), CD1a (B), CD3 (C) and CD68 (D).
Figure 2 Treatment response. Left panel: Sagittal imaging of the spinal cord tumor at the level of the 2nd-7th thoracic vertebrae by T2-weighted
MRI (upper row), T1-weighted, gadolinium enhanced MRI (middle row) and fusion with FDG-PET (lower row) taken at baseline (A), one month
(B) and three months (C) of vemurafenib therapy. There is gradual regression of the intramedullary tumor’s size, edema (T2 signal) and
contrast-enhancement. PET shows complete disappearance of FDG uptake in the tumor and substantial reduction in the bodies of the 6th
and 7th thoracic vertebrae. Right panel: whole body FDG-PET taken at the same time points showing gradual regression of hot-spots in the
patient’s skeleton and in particular the lower limbs.
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(Table 1). She stopped using the crutches and currently
walks unaided and reports a substantial increase in activ-
ities of daily function as well as improved quality of life.
She is now in the fourth month of treatment and toler-
ates the current dose well with only mild side-effects in
the form of intermittent, mild rubor and pain in the
small joints of the hands and feet and moderate skin
photosensitivity necessitating the use of sun-screen.
Conclusions
We show that vemurafenib is an effective and well tolerated
therapy for the treatment of intra-axial CNS infiltrative
lesions in ECD patients who are positive for the p.
V600E BRAF mutation, suggesting a neoplastic origin
of the disease. In spite of long-standing neurological
impairment, our patient showed substantial functional
improvement, which correlated well with the reduction
in lesion size and activity. This suggests that neuro-
logical dysfunction in ECD patients can have favorable
functional outcome with therapy irrespective of symptom
or disease duration.
Interestingly, a daily dose of 720 mg was sufficient to
elicit and maintain an ongoing positive clinical response
in our patient. This dose is substantially lower than the
recommended dose in metastatic malignant melanoma
(1920 mg daily) and even lower than the dose used in
the three reported ECD patients (960 mg daily) [16]. An
important challenge in treating ECD patients with
vemurafenib is that they require long-term treatment
with a compound which has substantial dose-dependent
toxicity. Progression free survival for metastatic mel-
anoma treated with vemurafenib is 6.9 months and
median follow up time in the BRIM-3 trial was
12.5 months [19]. Response duration in ECD patients
remains to be determined in clinical trials and long
term side effects, including secondary malignancies,
need to be carefully monitored. Our findings suggest
that the minimum-effective dose for ECD may be sub-
stantially lower than for other indications. This should
be considered in ongoing and future clinical trials and
low-dose regimes should be tested in order to determine
the minimum-effective dose for this group of patients.
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